Equity Overview
Price & Market Data
Price: $0.0801
Daily Change: -$0.015 / 18.73%
Daily Range: $0.078 - $0.0936
Market Cap: $21,283,676
Daily Volume: 34,590,556
Performance Metrics
1 Week: -19.38%
1 Month: -68.26%
3 Months: -73.23%
6 Months: -85.96%
1 Year: -93.14%
YTD: -85.09%
Company Details
Employees: 506
Sector: Health technology
Industry: Biotechnology
Country:
Details
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.